Mivazerol

Mivazerol is a drug that was developed for the treatment of ischemic heart disease. It is a selective alpha 2 adrenergic agonist.

Pharmacology

Mivazerol works by stimulating alpha 2 adrenergic receptors, which are found in the heart and blood vessels. This stimulation leads to a decrease in heart rate and blood pressure, which can be beneficial in the treatment of ischemic heart disease.

Clinical Trials

Mivazerol has been tested in several clinical trials. In one study, it was found to reduce the incidence of myocardial infarction (heart attack) in patients undergoing non-cardiac surgery. However, in another study, it did not show a significant benefit in reducing the risk of death or heart attack in patients with stable angina.

Side Effects

The most common side effects of mivazerol include dizziness, headache, and nausea. Less common side effects include bradycardia (slow heart rate), hypotension (low blood pressure), and dry mouth.

Development and Approval

Mivazerol was developed by Hoffmann-La Roche, a Swiss multinational healthcare company. However, it has not been approved for use by the Food and Drug Administration (FDA) in the United States.

See Also

• Ischemic heart disease
• Alpha 2 adrenergic agonist
• Clinical trial
• Hoffmann-La Roche

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

• 

  Mivazerol